Welcome To Jupiter Biomedical Research

Jupiter Biomedical Research, Inc. was created to commercialize two clinical development candidates, Viright and Avir, as well as additional drug candidates.

Cancer Treatment

The product based upon the first patent referenced above is being advanced as a potential cancer treatment. The product proposed is one which has the potential to treat countless numbers of humans suffering from the deadly disease of brain cancer. While there are some treatment options presently available, none are effective enough to keep brain cancer from being one of the most frightening and life-threatening diagnosis that can be made. Management believes that the drugs being developed by the Company have the potential to significantly affect the treatment of brain cancer. The science, drug testing, and protocol has been in development for over 30 years. It is only the last three years that the intellectual property has been protected by issued patents. Management now feels confident that we can move forward to begin regulatory compliance trials knowing that we have intellectual property protection.

Antiviral Treatment

The antiviral product is focused upon multiple sclerosis (MS) and SSPE. MS is characterized by acute exacerbations of neurological dysfunction with inter-current periods of improvement and quiescence. SSPE is a progressive, fatal disease of young children, directed at the Central Nervous System (CNS) caused by a persistent measles virus. The Company’s anti-viral drug, which we refer to as “ Avir“ is patented for treatment of Subacute Sclerosing Pan Encephalitis (SSPE) and Multiple Sclerosis (MS).